INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 152 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is 0.31 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $44,199 | +207.9% | 2,384 | +83.7% | 0.00% | +100.0% |
Q2 2023 | $14,356 | -17.6% | 1,298 | 0.0% | 0.00% | 0.0% |
Q1 2023 | $17,432 | -15.6% | 1,298 | -22.3% | 0.00% | 0.0% |
Q4 2022 | $20,658 | -11.3% | 1,670 | 0.0% | 0.00% | 0.0% |
Q3 2022 | $23,297 | +1.0% | 1,670 | 0.0% | 0.00% | 0.0% |
Q2 2022 | $23,063 | -15.1% | 1,670 | 0.0% | 0.00% | 0.0% |
Q1 2022 | $27,171 | -75.9% | 1,670 | -75.9% | 0.00% | -50.0% |
Q4 2021 | $112,906 | -3.9% | 6,931 | -12.4% | 0.00% | 0.0% |
Q3 2021 | $117,538 | -25.6% | 7,915 | 0.0% | 0.00% | 0.0% |
Q2 2021 | $158,063 | -13.5% | 7,915 | 0.0% | 0.00% | -33.3% |
Q1 2021 | $182,678 | -6.6% | 7,915 | 0.0% | 0.00% | 0.0% |
Q4 2020 | $195,501 | -40.4% | 7,915 | 0.0% | 0.00% | -50.0% |
Q3 2020 | $328,156 | -13.5% | 7,915 | 0.0% | 0.01% | -14.3% |
Q2 2020 | $379,208 | -19.5% | 7,915 | +5.8% | 0.01% | -30.0% |
Q1 2020 | $471,067 | -52.1% | 7,482 | -5.6% | 0.01% | -37.5% |
Q4 2019 | $982,686 | +82.5% | 7,930 | -2.3% | 0.02% | +77.8% |
Q3 2019 | $538,379 | -8.2% | 8,113 | +10.1% | 0.01% | -10.0% |
Q2 2019 | $586,351 | -26.9% | 7,369 | +2.8% | 0.01% | -33.3% |
Q1 2019 | $802,036 | +11.0% | 7,170 | 0.0% | 0.02% | +7.1% |
Q4 2018 | $722,664 | -20.2% | 7,170 | 0.0% | 0.01% | -12.5% |
Q3 2018 | $906,001 | -99.8% | 7,170 | 0.0% | 0.02% | +60.0% |
Q2 2018 | $601,635,000 | +632.0% | 7,170 | +436.7% | 0.01% | +900.0% |
Q1 2018 | $82,191,000 | +105273.1% | 1,336 | +0.1% | 0.00% | 0.0% |
Q4 2017 | $78,000 | 0.0% | 1,335 | -1.1% | 0.00% | – |
Q3 2017 | $78,000 | -49.7% | 1,350 | +5.4% | 0.00% | -100.0% |
Q2 2017 | $155,000 | +22.0% | 1,281 | +13.8% | 0.00% | 0.0% |
Q1 2017 | $127,000 | +4.1% | 1,126 | 0.0% | 0.00% | 0.0% |
Q4 2016 | $122,000 | -37.1% | 1,126 | -4.4% | 0.00% | 0.0% |
Q3 2016 | $194,000 | +10.2% | 1,178 | -4.5% | 0.00% | 0.0% |
Q2 2016 | $176,000 | +14.3% | 1,234 | +3.2% | 0.00% | 0.0% |
Q1 2016 | $154,000 | -14.0% | 1,196 | 0.0% | 0.00% | 0.0% |
Q4 2015 | $179,000 | -7.3% | 1,196 | +2.7% | 0.00% | 0.0% |
Q3 2015 | $193,000 | -31.3% | 1,164 | 0.0% | 0.00% | -50.0% |
Q2 2015 | $281,000 | +6.0% | 1,164 | +23.7% | 0.00% | 0.0% |
Q1 2015 | $265,000 | +93.4% | 941 | +7.1% | 0.00% | +100.0% |
Q4 2014 | $137,000 | -32.5% | 879 | +2.7% | 0.00% | 0.0% |
Q3 2014 | $203,000 | -0.5% | 856 | -0.7% | 0.00% | 0.0% |
Q2 2014 | $204,000 | -89.0% | 862 | -84.7% | 0.00% | -92.3% |
Q1 2014 | $1,856,000 | +380.8% | 5,628 | -0.4% | 0.01% | +333.3% |
Q4 2013 | $386,000 | -1.0% | 5,652 | 0.0% | 0.00% | 0.0% |
Q3 2013 | $390,000 | +54.2% | 5,652 | 0.0% | 0.00% | +50.0% |
Q2 2013 | $253,000 | – | 5,652 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |